These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 16004673)

  • 1. The impact of topical cyclosporine A emulsion 0.05% on the outcomes of patients with keratoconjunctivitis sicca.
    Stonecipher K; Perry HD; Gross RH; Kerney DL
    Curr Med Res Opin; 2005 Jul; 21(7):1057-63. PubMed ID: 16004673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Self-reported compliance with topical cyclosporine emulsion 0.05% and onset of the effects of increased tear production as assessed through patient surveys.
    Trattler W; Katsev D; Kerney D
    Clin Ther; 2006 Nov; 28(11):1848-56. PubMed ID: 17213005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren syndrome.
    Marsh P; Pflugfelder SC
    Ophthalmology; 1999 Apr; 106(4):811-6. PubMed ID: 10201607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flow cytometric analysis of inflammatory markers in KCS: 6-month treatment with topical cyclosporin A.
    Brignole F; Pisella PJ; De Saint Jean M; Goldschild M; Goguel A; Baudouin C
    Invest Ophthalmol Vis Sci; 2001 Jan; 42(1):90-5. PubMed ID: 11133852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Flow cytometry in impression cytology during keratoconjunctivitis sicca: effects of topical cyclosporin A on HLA DR expression].
    Galatoire O; Baudouin C; Pisella PJ; Brignole F
    J Fr Ophtalmol; 2003 Apr; 26(4):337-43. PubMed ID: 12843889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topical 0.1% prednisolone lowers nerve growth factor expression in keratoconjunctivitis sicca patients.
    Lee HK; Ryu IH; Seo KY; Hong S; Kim HC; Kim EK
    Ophthalmology; 2006 Feb; 113(2):198-205. PubMed ID: 16360211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of an isotonic tear in combination with topical cyclosporine for the treatment of ocular surface disease.
    Hardten DR; Brown MJ; Pham-Vang S
    Curr Med Res Opin; 2007 Sep; 23(9):2083-91. PubMed ID: 17822610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topical administration of cyclosporine for treatment of keratoconjunctivitis sicca in dogs.
    Morgan RV; Abrams KL
    J Am Vet Med Assoc; 1991 Oct; 199(8):1043-6. PubMed ID: 1748607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Topical cyclosporine A 0.05% in the treatment of keratoconjunctivitis sicca].
    Schrell C; Cursiefen C; Kruse F; Jacobi C
    Klin Monbl Augenheilkd; 2012 May; 229(5):548-53. PubMed ID: 22189827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years.
    Barber LD; Pflugfelder SC; Tauber J; Foulks GN
    Ophthalmology; 2005 Oct; 112(10):1790-4. PubMed ID: 16102833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical evaluation of 1% cyclosporine for topical treatment of keratoconjunctivitis sicca in dogs.
    Olivero DK; Davidson MG; English RV; Nasisse MP; Jamieson VE; Gerig TM
    J Am Vet Med Assoc; 1991 Oct; 199(8):1039-42. PubMed ID: 1748606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of sequential artificial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor-beta2 production.
    Pflugfelder SC; De Paiva CS; Villarreal AL; Stern ME
    Cornea; 2008 Jan; 27(1):64-9. PubMed ID: 18245969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical evaluation of pimecrolimus eye drops for treatment of canine keratoconjunctivitis sicca: a comparison with cyclosporine A.
    Ofri R; Lambrou GN; Allgoewer I; Graenitz U; Pena TM; Spiess BM; Latour E
    Vet J; 2009 Jan; 179(1):70-7. PubMed ID: 17950639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Self-reported treatment impressions and satisfaction of papulopustular rosacea patients treated with doxycycline, USP, 40 mg capsules.
    Johnson SM; LeVine P
    J Drugs Dermatol; 2011 Dec; 10(12):1376-81. PubMed ID: 22134561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of cyclosporine 0.05% drops versus unpreserved artificial tears in dry-eye patients having laser in situ keratomileusis.
    Salib GM; McDonald MB; Smolek M
    J Cataract Refract Surg; 2006 May; 32(5):772-8. PubMed ID: 16765793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of topical dry eye medications for the treatment of keratoconjunctivitis sicca in a botulinum toxin B-induced mouse model.
    Lekhanont K; Leyngold IM; Suwan-Apichon O; Rangsin R; Chuck RS
    Cornea; 2007 Jan; 26(1):84-9. PubMed ID: 17198019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of cyclosporine 0.05% ophthalmic emulsion in contact lens wearers with dry eyes.
    Willen CM; McGwin G; Liu B; Owsley C; Rosenstiel C
    Eye Contact Lens; 2008 Jan; 34(1):43-5. PubMed ID: 18180683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
    Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
    Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment.
    Wilson SE; Perry HD
    Ophthalmology; 2007 Jan; 114(1):76-9. PubMed ID: 17070588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of topical 0.02% tacrolimus aqueous suspension on tear production in dogs with keratoconjunctivitis sicca.
    Berdoulay A; English RV; Nadelstein B
    Vet Ophthalmol; 2005; 8(4):225-32. PubMed ID: 16008701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.